1314 E LAS OLAS BLVD, SUITE 221, FORT LAUDERDALE, FL
Unregistered Sales of Equity Securities
Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Endovia Health Sciences Secures $510,000 Investment from C/M Capital
Closes Initial $500,000 Financing to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
Employment Agreements with Brady Cobb and Michael Bondurant Signed
Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
Q2
Notice of Late Filing for Quarterly Report
Q1
Amended Annual Report
FY 2025
Notice of Late Filing for Annual Report
Q3
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Submission Upload
Correspondence